Abbot launches study comparing OCT to angiography in stent placement procedures

Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography. The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said. “Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT provides just that, the ability to look at the artery from the outside-in and the inside-out. I’m confident this technology will have a positive impact on clinical practice around the world and we hope to provide evidence for leading medical organizations to update clinical guidelines for stent implantation based on the results of this study,” co-principal investigator Dr. Ziad Al of  Columbia University Medical Center said in a prepared statement. In the Ilumien IV trial, which Abbott claims is the first large-scale study of its kind to explore the use of OCT imaging in patients with high-risk complex coronary artery disease, a total of 3,650 patients will be randomly assigned to either OCT or angiography guided placement of one or more Xience everolimus-eluting coronary stents. During OCT-guided procedures, physicians use high-resolution images ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news